CoChat

GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells

Open access
Cohen, Yossi, Gutwein, Odit, Garach-Jehoshua, Osnat, Bar-Haim, Adina, Kornberg, Abraham · 2013 · Hematology

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

In a comparison of gene expression profile in unsorted bone marrow (BM) samples from patients with multiple myeloma (MM), acute leukemia, and diffuse large B-cell lymphoma infiltrating the BM, the leading myeloma distinguishing gene was GPRC5D. This gene was highly expressed in BM samples from the 10 MM cases examined as opposed to minimal expression in samples from the eight cases with other hematological malignancies. Moreover, following antimyeloma treatment the expression of GPRC5D decreased several folds. The strong and selective expression of GPRC5D in MM cells makes this gene and its encoded surface protein as promising markers for monitoring the tumor load and hopefully also as targets for antimyeloma antibodies.

Overview

Integrity signals

Registry

Crossref · 10.1179/1607845413y.0000000079

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 1

  1. Pilarski LM, 2008, Clin Med Oncol., 2, 275

Cited by

See all 54

Metadata

Authors
Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A., & Kornberg, A.
Affiliations
  • Tel Aviv University (IL)
  • Hematology LaboratoryAssaf Harofeh Medical Center, Zerifin, Israel, Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Israel
Corresponding author
Cohen, Yossi
Venue
Hematology
Published
2013-11
Volume
18
Issue
6
Pages
348-351
ISSN
  • 1024-5332 (ISSN-L)
  • 1607-8454
OpenAlex
W2011876556
Cited by
54
References
5
Citations by year
2026: 5 · 2025: 6 · 2024: 12 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 6 · 2018: 1 · 2017: 1 · 2014: 1
FWCI
0.24
Type
journal article
Language
en
Open access
Locations
  • Hematology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agilent Technologies
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
Keywords
GPRC5D, multiple myeloma, bone marrow, gene expression profiling, hematologic malignancies, acute leukemia, diffuse large B-cell lymphoma, therapeutic target, monoclonal antibodies, minimal residual disease
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Multiple Myeloma, Biomarkers, Tumor, Receptors, G-Protein-Coupled, Tumor Burden, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. https://app.cochat.ai/papers/10.1179/1607845413y.0000000079
The paper
Cohen, Y., Gutwein, O., Garach-Jehoshua, O., Bar-Haim, A., & Kornberg, A. (2013). GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. https://doi.org/10.1179/1607845413y.0000000079

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.